NCT ID NCT05609370

Title A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus

Capecitabine Versus Bevacizumab Plus Capecitabine in Participants With Unresectable or Metastatic Colorectal Cancer

Phase 1, Phase 2

Date Added 2022-11-08

Location Alaska, United States

Arizona, United States
California, United States
Florida, United States
Indiana, United States
Indiana, United States
Kentucky, United States
Louisiana, United States
Missouri, United States
Montana, United States
Nevada, United States
New Mexico, United States
New York, United States
North Carolina, United States
Tennessee, United States
Texas, United States

Australia China Puerto Rico

Virginia, United States Washington, United States

Prior IO Allowed No
CRC-directed Yes

Status Active, not recruiting

Drugs Bevacizumab, capecitabine, LBL-007, Tislelizumab

Tags MSS/ MMRp

NCT ID NCT04085185

Title A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors

PhasePhase 1Date Added2019-09-11LocationChinaPrior IO AllowedYesCRC-directedNo

Status Recruiting

Drugs IBI110, IBI110+ Sintilimab, IBI110, Sintilinab

Tags MSI-H/ MMRd, MSS/ MMRp

NCT ID NCT04009681

Title A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid

Tumors

Phase Phase 1, Phase 2

Date Added 2019-07-05

Location Arizona, United States

Colorado, United States Florida, United States Tennessee, United States Texas, United States

Argentina Australia Chile Singapore Spain

Prior IO Allowed No

CRC-directed No

Status Terminated

Drugs anti-EGFR antibody, Checkpoint inhibitor, THOR-707

Tags MSI-H/ MMRd, MSS/ MMRp

NCT ID NCT05653882

Title A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors

 Phase
 Phase 1

 Date Added
 2022-12-16

Location California, United States

Florida, United States
Illinois, United States
Massachusetts, United States
Michigan, United States
Missouri, United States
New Jersey, United States
New York, United States
North Carolina, United States
Oregon, United States

Connecticut, United States

Tennessee, United States Utah, United States Virginia, United States

Prior IO Allowed Yes
CRC-directed No

Status Active, not recruiting

Drugs

Tags MSI-H/ MMRd, MSS/ MMRp

NCT ID NCT05491317

Title A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With

Metastatic Solid Tumors

PhasePhase 1, Phase 2Date Added2022-08-08LocationFrancePrior IO AllowedYes

Status Terminated

Drugs Pembrolizumab

Tags MSI-H/ MMRd, MSS/ MMRp

No

NCT ID NCT06513221

Title A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy,

Bevacizumab Combined With Adebrelimab

Phase

CRC-directed

Date Added 2024-07-22

Location

Prior IO Allowed No CRC-directed Yes

Status

Drugs

Tags MSS/ MMRp

NCT ID NCT03981146

Title A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer

PhasePhase 2Date Added2019-06-10LocationUnited Kingdom

Prior IO Allowed No CRC-directed Yes

StatusActive, not recruitingDrugsNivolumab, OpdivoTagsMSS/ MMRp

NCT ID NCT05205330

Title A Phase Ib/IIa Study of CR6086 in Combination With Balstilimab in pMMR-MSS Metastatic Colorectal Cancer Patients

Phase 1, Phase 2

Date Added 2022-01-25

 Location
 Italy

 Prior IO Allowed
 No

 CRC-directed
 Yes

Status Active, not recruiting

Drugs AGEN2034, Balstilimab, CR6086

Tags MSS/ MMRp

NCT ID NCT04550897

Title A Phase I/II Study With BM7PE Immunotoxin in Colorectal Cancer Patients

PhasePhase 1Date Added2020-09-16LocationNorwayPrior IO AllowedYesCRC-directedYesStatusRecruiting

Drugs BM7PE

Tags MSI-H/ MMRd, MSS/ MMRp

NCT ID NCT06508307

Title A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors

PhasePhase 1Date Added2024-07-18LocationChinaPrior IO AllowedYesCRC-directedYesStatusRecruiting

Drugs

Tags MSI-H/ MMRd, MSS/ MMRp